HRP20231448T1 - Primjena delgocitiniba za liječenje kroničnog ekcema ruku - Google Patents
Primjena delgocitiniba za liječenje kroničnog ekcema ruku Download PDFInfo
- Publication number
- HRP20231448T1 HRP20231448T1 HRP20231448TT HRP20231448T HRP20231448T1 HR P20231448 T1 HRP20231448 T1 HR P20231448T1 HR P20231448T T HRP20231448T T HR P20231448TT HR P20231448 T HRP20231448 T HR P20231448T HR P20231448 T1 HRP20231448 T1 HR P20231448T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- treatment
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 title claims 2
- 208000010668 atopic eczema Diseases 0.000 title claims 2
- 230000001684 chronic effect Effects 0.000 title claims 2
- 229940125772 JTE-052 Drugs 0.000 title 1
- LOWWYYZBZNSPDT-ZBEGNZNMSA-N delgocitinib Chemical compound C[C@H]1CN(C(=O)CC#N)[C@@]11CN(C=2C=3C=CNC=3N=CN=2)CC1 LOWWYYZBZNSPDT-ZBEGNZNMSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Storage Of Fruits Or Vegetables (AREA)
Claims (6)
1. Spoj opće formule (I)
[image]
3-[(3S,4R)-3-metil-6-(7H-pirolo[2,3d]pirimidin-4-il)-1,6-diazaspiro[3,4]oktan-1-il]-3-oksopropannitril, ili njegova farmaceutski prihvatljiva sol za upotrebu u liječenju kroničnog ekcema ruku, pri čemu se spoj formule (I), ili njegova farmaceutski prihvatljiva sol, primjenjuje primjenom dva puta dnevno i pri čemu je liječenje lokalno liječenje.
2. Spoj za upotrebu prema zahtjevu 1, naznačen time što se spoj formule (I) ili njegova farmaceutski prihvatljiva sol primjenjuje u obliku masti.
3. Spoj za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što se spoj formule (I), ili njegova farmaceutski prihvatljiva sol, primjenjuje u koncentraciji od 30 mg/g.
4. Spoj za upotrebu prema bilo kojem od prethodnih zahtjeva 1-2, naznačen time što se spoj formule (I) ili njegova farmaceutski prihvatljiva sol primjenjuje u farmaceutskom pripravku u koncentraciji od 2,00 tež.% cjelokupnog farmaceutskog pripravka.
5. Spoj za upotrebu u skladu s bilo kojim od prethodnih zahtjeva, naznačen time što se spoj formule (I) ili njegova farmaceutski prihvatljiva sol primjenjuje dva puta dnevno tijekom 8 tjedana.
6. Spoj za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što se spoj formule (I), ili njegova farmaceutski prihvatljiva sol, primjenjuje u količini od 1,7 mg/cm2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16152215 | 2016-01-21 | ||
EP17701828.0A EP3405197B1 (en) | 2016-01-21 | 2017-01-20 | Use of delgocitinib for the treatment of chronic hand eczema |
PCT/EP2017/051133 WO2017125523A1 (en) | 2016-01-21 | 2017-01-20 | Treatment of hand eczema |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231448T1 true HRP20231448T1 (hr) | 2024-03-01 |
Family
ID=55236207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231448TT HRP20231448T1 (hr) | 2016-01-21 | 2017-01-20 | Primjena delgocitiniba za liječenje kroničnog ekcema ruku |
Country Status (25)
Country | Link |
---|---|
US (2) | US20200397787A1 (hr) |
EP (2) | EP4257205A3 (hr) |
JP (1) | JP6929860B2 (hr) |
KR (1) | KR20180102662A (hr) |
CN (3) | CN117159554A (hr) |
AU (2) | AU2017209932A1 (hr) |
BR (1) | BR112018014769A2 (hr) |
CA (1) | CA3010547A1 (hr) |
DK (1) | DK3405197T3 (hr) |
ES (1) | ES2963784T3 (hr) |
FI (1) | FI3405197T3 (hr) |
HR (1) | HRP20231448T1 (hr) |
HU (1) | HUE064192T2 (hr) |
IL (2) | IL297379A (hr) |
LT (1) | LT3405197T (hr) |
MX (2) | MX2018008449A (hr) |
PL (1) | PL3405197T3 (hr) |
PT (1) | PT3405197T (hr) |
RS (1) | RS64798B1 (hr) |
RU (1) | RU2018130097A (hr) |
SG (2) | SG11201805394QA (hr) |
SI (1) | SI3405197T1 (hr) |
TW (1) | TWI783921B (hr) |
UA (1) | UA123780C2 (hr) |
WO (1) | WO2017125523A1 (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3968997A1 (en) * | 2019-05-15 | 2022-03-23 | Leo Pharma A/S | Treatment of cutaneous lupus erythematosus |
WO2022167913A1 (en) * | 2021-02-02 | 2022-08-11 | Pfizer Inc. | Dosing regime for treatment of chronic hand eczema |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
US20130302298A1 (en) * | 2010-11-30 | 2013-11-14 | Bio-K Plus International Inc. | Treatment and prevention of eczema |
US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
-
2017
- 2017-01-20 HR HRP20231448TT patent/HRP20231448T1/hr unknown
- 2017-01-20 DK DK17701828.0T patent/DK3405197T3/da active
- 2017-01-20 FI FIEP17701828.0T patent/FI3405197T3/fi active
- 2017-01-20 WO PCT/EP2017/051133 patent/WO2017125523A1/en active Application Filing
- 2017-01-20 EP EP23195420.7A patent/EP4257205A3/en active Pending
- 2017-01-20 RU RU2018130097A patent/RU2018130097A/ru unknown
- 2017-01-20 AU AU2017209932A patent/AU2017209932A1/en not_active Abandoned
- 2017-01-20 PT PT177018280T patent/PT3405197T/pt unknown
- 2017-01-20 RS RS20231010A patent/RS64798B1/sr unknown
- 2017-01-20 CN CN202311350784.6A patent/CN117159554A/zh active Pending
- 2017-01-20 BR BR112018014769-9A patent/BR112018014769A2/pt active Search and Examination
- 2017-01-20 JP JP2018538167A patent/JP6929860B2/ja active Active
- 2017-01-20 HU HUE17701828A patent/HUE064192T2/hu unknown
- 2017-01-20 SI SI201731440T patent/SI3405197T1/sl unknown
- 2017-01-20 PL PL17701828.0T patent/PL3405197T3/pl unknown
- 2017-01-20 US US16/071,209 patent/US20200397787A1/en not_active Abandoned
- 2017-01-20 KR KR1020187024112A patent/KR20180102662A/ko active Search and Examination
- 2017-01-20 MX MX2018008449A patent/MX2018008449A/es unknown
- 2017-01-20 SG SG11201805394QA patent/SG11201805394QA/en unknown
- 2017-01-20 CN CN201780006075.2A patent/CN108472297A/zh active Pending
- 2017-01-20 EP EP17701828.0A patent/EP3405197B1/en active Active
- 2017-01-20 ES ES17701828T patent/ES2963784T3/es active Active
- 2017-01-20 CA CA3010547A patent/CA3010547A1/en active Pending
- 2017-01-20 LT LTEPPCT/EP2017/051133T patent/LT3405197T/lt unknown
- 2017-01-20 UA UAA201808829A patent/UA123780C2/uk unknown
- 2017-01-20 SG SG10202006830WA patent/SG10202006830WA/en unknown
- 2017-01-20 CN CN202311350781.2A patent/CN117159553A/zh active Pending
- 2017-01-20 IL IL297379A patent/IL297379A/en unknown
- 2017-01-20 TW TW106102111A patent/TWI783921B/zh active
-
2018
- 2018-06-18 IL IL260094A patent/IL260094A/en unknown
- 2018-07-09 MX MX2022005915A patent/MX2022005915A/es unknown
-
2022
- 2022-07-08 US US17/811,347 patent/US20230138114A1/en active Pending
- 2022-10-13 AU AU2022252766A patent/AU2022252766A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
SG10201804024VA (en) | Formulations of azaindole compounds | |
HRP20171175T1 (hr) | Novi triciklički spojevi | |
HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
HRP20161295T1 (hr) | Primjena antitumorskog sredstva | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
CL2012002318A1 (es) | Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer. | |
WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
NZ714963A (en) | Compositions and methods for treating anemia | |
WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
JP2012236857A5 (hr) | ||
HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
HRP20230935T1 (hr) | Postupci za liječenje i profilaksu hiv-a i aids-a | |
MX2021014029A (es) | Formulaciones, fabricación y usos de imatinib. | |
HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
MX2019001596A (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
BR112015014433A2 (pt) | compostos tricíclicos | |
HRP20231448T1 (hr) | Primjena delgocitiniba za liječenje kroničnog ekcema ruku | |
HRP20200472T1 (hr) | Liječenje alopecije areate |